| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $96.7M | +13.5% |
| SG&A Expense | $44.5M | +31.3% |
| Operating Income | -$141.2M | -18.5% |
| Income Tax | $0 | — |
| Net Income | -$136.6M | -14.7% |
| EPS (Basic) | -$2.35 | -10.8% |
| EPS (Diluted) | -$2.35 | -10.8% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $93.2M | -75.2% |
| Short-term Investments | $185.9M | — |
| Accounts Receivable | $395K | — |
| Current Assets | $287.0M | -24.3% |
| Total Assets | $376.3M | -21.1% |
| Current Liabilities | $19.1M | +1.8% |
| Total Liabilities | $93.8M | -1.3% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$102.4M | -11.6% |
| Capital Expenditures | $8.8M | +47.7% |
| Investing Cash Flow | -$192.5M | -199.7% |
| Financing Cash Flow | $13.0M | -93.9% |
| Free Cash Flow | -$111.2M | -13.8% |
| Stockholders' Equity |
| $282.5M |
| -26.0% |